Notch1 receptor binding agents and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9499613-B2
Application number	US-201414577484-A
Country	US
Kind code	B2
Filing date	Dec 19, 2014
Priority date	Jul 8, 2008
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

First claim

What is claimed is:

1. A method of inhibiting activity of Notch1 in a cell, comprising contacting the cell with an effective amount of an antibody that specifically binds human Notch1, wherein the antibody comprises:
(a) a heavy chain CDR1 comprising RGYWIE (SEQ ID NO:15); a heavy chain CDR2 comprising QILPGTGRTNYNEKFKG (SEQ ID NO:16); and a heavy chain CDR3 comprising FDGNYGYYAMDY (SEQ ID NO:17); and
(b) a light chain CDR1 comprising RSSTGAVTTSNYAN (SEQ ID NO:18); a light chain CDR2 comprising GTNNRAP (SEQ ID NO:19); and a light chain CDR3 comprising ALWYSNHWVFGGGTKL (SEQ ID NO:20).

2. The method of claim 1 , wherein the antibody binds to a non-ligand binding membrane proximal region of an extracellular domain of human Notch1 receptor.

3. The method of claim 2 , wherein the non-ligand binding membrane proximal region of an extracellular domain of human Notch1 receptor comprises SEQ ID NO:2.

4. The method of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:14 or SEQ ID NO:24; and
(b) a light chain variable region having at least 90% sequence identity to SEQ ID NO:8, SEQ ID NO:28, or SEQ ID NO:32.

5. The method of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable region comprising SEQ ID NO:24; and
(b) a light chain variable region comprising SEQ ID NO:28.

6. The method of claim 1 , wherein the antibody comprises:
(a) a heavy chain variable region comprising SEQ ID NO:24; and
(b) a light chain variable region comprising SEQ ID NO:32.

7. The method of claim 1 , wherein the antibody is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, an antibody fragment, a bispecific antibody, a monospecific antibody, a monovalent antibody, an IgG1 antibody, or an IgG2 antibody.

8. The method of claim 1 , wherein the antibody is a monoclonal antibody.

9. The method of claim 8 , wherein the antibody is a humanized antibody.

10. The method of claim 1 , wherein the antibody is 52M51H4L3.

11. The method of claim 1 , wherein the cell is a tumor cell.

12. The method of claim 11 , wherein the antibody inhibits growth of the tumor cell.

13. A method of inhibiting growth of a tumor or a tumor cell, comprising contacting the tumor or tumor cell with an effective amount of an antibody that specifically binds human Notch1, wherein the antibody comprises:
(a) a heavy chain CDR1 comprising RGYWIE (SEQ ID NO:15); a heavy chain CDR2 comprising QILPGTGRTNYNEKFKG (SEQ ID NO:16); and a heavy chain CDR3 comprising FDGNYGYYAMDY (SEQ ID NO:17); and
(b) a light chain CDR1 comprising RSSTGAVTTSNYAN (SEQ ID NO:18); a light chain CDR2 comprising GTNNRAP (SEQ II) NO:19): and a light chain CDR3 comprising ALWYSNHWVFGGGTKL (SEQ ID NO:20).

14. The method of claim 13 , wherein the antibody binds to a non-ligand binding membrane proximal region of an extracellular domain of human Notch1 receptor.

15. The method of claim 13 , wherein the non-ligand binding membrane proximal region of an extracellular domain of human Notch1 receptor comprises SEQ ID NO:2.

16. The method of claim 13 , wherein the antibody comprises:
(a) a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:14 or SEQ ID NO:24; and
(b) a light chain variable region having at least 90% sequence identity to SEQ ID NO:8, SEQ II) NO:28, or SEQ ID NO:32.

17. The method of claim 13 , wherein the antibody comprises:
(a) a heavy chain variable region comprising SEQ NO:24; and
(b) a light chain variable region comprising SEQ ID NO:28.

18. The method of claim 13 , wherein the antibody comprises:
(a) a heavy chain variable region comprising SEQ ID NO:24; and
(b) a light chain variable region comprising SEQ ID NO:32.

19. The method of claim 13 , wherein the antibody is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, an antibody fragment, a bispecific antibody, a monospecific antibody, a monovalent antibody, an IgG1 antibody, or an IgG2 antibody.

20. The method of claim 13 , wherein the antibody is a monoclonal antibody.

21. The method of claim 20 , wherein the antibody is a humanized antibody.

22. The method of claim 13 , wherein the antibody is 52M51H4L3.

23. The method of claim 13 , wherein the tumor is selected from the group consisting of a lung tumor, pancreatic tumor, ovarian tumor, breast tumor, colorectal tumor, hepatic tumor, renal tumor, prostate tumor, and head and neck tumor.

Assignees

• Oncomed Pharm Inc

Inventors

• Gurney Austin L
• Hoey Timothy Charles
• Bruhns Maureen Fitch
• Axelrod Fumiko Takada

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/04

  specific for metastasis · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title